Journal
JOURNAL OF CONTROLLED RELEASE
Volume 324, Issue -, Pages 482-492Publisher
ELSEVIER
DOI: 10.1016/j.jconrel.2020.05.043
Keywords
Non-small cell lung cancer; Epidermal growth factor receptor; Tyrosine kinase inhibitor; EGFR-TKIs resistance; Nanotechnology
Funding
- Taiwan Ministry of Science and Technology [MOST108-2628-B-110-001, MOST108-2628-E-110-MY3, MOST108-3114-Y-001-002, MOST107-0210-01-19-01]
- Academia Sinica [AS-SUMMIT-108]
Ask authors/readers for more resources
Lung cancer is the primary cause of cancer-related death worldwide. 85%-90% of cases are non-small cell lung cancer (NSCLC) which characteristically exhibits altered epidermal growth factor receptor (EGFR) signaling is a major driver pathway. Unfortunately, therapeutic outcomes in treating NSCLC are compromised by the emergence of drug resistance in response to EGFR-tyrosine kinase inhibitor (TKI) targeted therapy due to the acquired resistance mutation EGFR T790M or activation of alternative pathways. There is current need for a new generation of TKIs to be developed to treat EGFR-TKI-resistant NSCLC. To overcome the above problems and improve clinical efficacy, nanotechnology with targeting abilities and sustained release has been proposed for EGFR-TKI-resistant NSCLC treatment and has already achieved success in in vitro or in vivo models. In this review, we summarize and illustrate representative nano-formulations targeting EGFR-TKI-resistant NSCLC. The described advances may pave the way to better understanding and design of nanocarriers and multifunctional nanosystems for efficient treatment for drug resistant NSCLC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available